These therapies target immune inhibitory pathways, such as cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) and programmed cell death protein 1 (PD-1), to enhance anti-tumour immune responses [5,6]. This evidence concerns the gene CTLA4 and neoplasm.